EUVIMEDDescobrir EUVIMED
Open access · CC BY 4.0

Linker Engineering of Hybrid Triazole-Thiazolidine Antifungals Identifies a Promising Lead Against Drug-Resistant Candida Species

Alexander Yu Rudenko, Olga A Komarova, Alexander Yu Simonov, Ratislav M Ozhiganov iD, Dmitrii A Averianov, Sofiia R Kuklich, Ekaterina A Guseva iD, Sofya Y Sokolskaya, Lyudmila G Kuz'mina, Natalia E Grammatikova iD, Alexander B Kulko, Victoria A Bidiuk iD and 6 more

Pharmaceuticals · 2026-08-10 · 19 (8) · 1260

DOI: 10.3390/ph19081260 ↗

At a glance

Journal article in Pharmaceuticals, published online on 2026-08-10. Written by Alexander Yu Rudenko and 17 co-authors. Institution: Belozersky Institute of Physico-Chemical Biology, M.V. Lomonosov Moscow State University, 119991 Moscow, Russia. 56 references. The full text is freely available (open access, CC BY 4.0). Funded by: Russian Science Foundation.

ResumoSubjectsDados bibliográficosCiteRelated studies

Abstract (original language)

Background

The emergence of antifungal resistance and the limited number of clinically available antifungal drug classes necessitate the development of new agents with improved efficacy and safety. We investigated how linker architecture influences the antifungal activity and lead properties of hybrid triazole-thiazolidine derivatives.

Methods

A focused library of triazole-thiazolidine hybrids incorporating alkylamine, amide, cyclic amine, 2-hydroxypropyl, and thiazepane linkers was synthesized and characterized. Antifungal activity was evaluated against reference strains and clinical isolates of Candida spp., Aspergillus fumigatus, dermatophytes, and Cryptococcus neoformans. Structure–activity relationships were analyzed by molecular docking. Selected compounds were further assessed by SCRAPPY profiling, fluorescence microscopy, mammalian-cell cytotoxicity assays, acute oral toxicity studies, and evaluation of microsomal stability and interactions with human CYP450 isoforms.

Results

Linker architecture strongly influenced antifungal potency. Amide- and cyclic amine-containing hybrids were generally the most active, whereas simple alkylamide derivatives showed narrower activity profiles. Compound 28 emerged as the most promising lead, exhibiting sub-microgram MIC values against several Candida isolates, particularly C. parapsilosis, and retaining measurable activity against an azole-resistant C. albicans strain. Docking generated putative CYP51-binding models, while SCRAPPY profiling and fluorescence microscopy revealed an azole-like cellular response consistent with perturbation of sterol-associated homeostasis. Compound 28 was tolerated at 300 mg/kg in an acute oral study but showed concentration- and time-dependent cytotoxicity and rapid CYP3A4-mediated microsomal metabolism.

Conclusions

Systematic variation of linker architecture identified compound 28 as a promising exploratory antifungal lead. Further optimization should focus on improving metabolic stability and cytotoxicity, together with direct target validation, pharmacokinetic characterization, and in vivo efficacy studies.

Subjects

Author keywords

CYP51Candida aurisCandida spp.antifungal activityazole resistanceergosterol biosynthesistriazole-thiazolidine hybrids

Authors and institutions

  • Belozersky Institute of Physico-Chemical Biology, M.V. Lomonosov Moscow State University, 119991 Moscow, Russia.
  • Chemical Department, M.V. Lomonosov Moscow State University, 119991 Moscow, Russia.
  • Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya 16/10, 117997 Moscow, Russia.
  • Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, 119021 Moscow, Russia.
  • Faculty of Fundamental Medicine, M.V. Lomonosov Moscow State University, 119991 Moscow, Russia.
  • N.S. Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, 119991 Moscow, Russia.

ORCID profiles: Ratislav M Ozhiganov, Ekaterina A Guseva, Natalia E Grammatikova, Victoria A Bidiuk, Sofia S Mariasina, Vasiliy A Ivlev, Peter V Sergiev, Vladimir I Polshakov

Funding

  • Russian Science Foundation

Cite

APA

Rudenko, A. Y., Komarova, O. A., Simonov, A. Y., Ozhiganov, R. M., Averianov, D. A., Kuklich, S. R., Guseva, E. A., Sokolskaya, S. Y., Kuz'mina, L. G., Grammatikova, N. E., Kulko, A. B., Bidiuk, V. A., Mariasina, S. S., Ivlev, V. A., Sergiev, P. V., Polshakov, V. I., Mantsyzov, A. B., & Levshin, I. B. (2026). Linker Engineering of Hybrid Triazole-Thiazolidine Antifungals Identifies a Promising Lead Against Drug-Resistant Candida Species. Pharmaceuticals, 19(8), 1260. https://doi.org/10.3390/ph19081260

Vancouver

Rudenko AY, Komarova OA, Simonov AY, Ozhiganov RM, Averianov DA, Kuklich SR, et al. Linker Engineering of Hybrid Triazole-Thiazolidine Antifungals Identifies a Promising Lead Against Drug-Resistant Candida Species. Pharmaceuticals. 2026;19(8):1260. doi:10.3390/ph19081260

BibTeX
@article{Rudenko2026,
  author = {Rudenko, Alexander Yu and Komarova, Olga A and Simonov, Alexander Yu and Ozhiganov, Ratislav M and Averianov, Dmitrii A and Kuklich, Sofiia R and Guseva, Ekaterina A and Sokolskaya, Sofya Y and Kuz'mina, Lyudmila G and Grammatikova, Natalia E and Kulko, Alexander B and Bidiuk, Victoria A and Mariasina, Sofia S and Ivlev, Vasiliy A and Sergiev, Peter V and Polshakov, Vladimir I and Mantsyzov, Alexey B and Levshin, Igor B},
  title = {Linker Engineering of Hybrid Triazole-Thiazolidine Antifungals Identifies a Promising Lead Against Drug-Resistant Candida Species},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {8},
  pages = {1260},
  doi = {10.3390/ph19081260}
}
Start for free →